Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 11
Submit an article Journal homepage
98
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Rosuvastatin: a risk–benefit assessment for intensive lipid lowering

Keith C Ferdinand Xavier University, College of Pharmacy, USA; Heartbeats Life Center, 1201 Poland Avenue, New Orleans, LA 70117, USA. [email protected]
Pages 1897-1910 | Published online: 07 Sep 2005

Bibliography

  • EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2001) 285:2486–2497.
  • STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N EngL J. Med. (2002) 346:539–540.
  • GRUNDY SM, CLEEMAN JI, CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.. (2004) 110:227–239.
  • CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus lipid lowering with statins after acute coronary syndromes. N Engl. J. Med. (2004) 350:1495–1504.
  • HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
  • SHEPHERD J, BLAUW GJ, MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623–1630.
  • ALLHAT OFFICERS AND FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT-LLT). (2002) 288:2998–3007.
  • SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stoke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering ARM (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. (2003) 361:1149–1158.
  • COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. (2004) 364:685–696.
  • LAROSA JC, GRUNDY SM, DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl. J. Med. (2005) 352:1425–1435.
  • JONES PH, DAVIDSON MH, STEIN EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol (2003) 93:152–160.
  • MICHALETS EL: Clinically significant cytochrome P-450 drug interaction-author's reply. Pharmacotherapy (1998) 18:892–893.
  • GUENGERICH FP: Cyotchrome P-450 3A4: regulation and role in drug metabolism. Ann. Rev. Pharmacol (1999) 39:1–17.
  • BREWER HB JR: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams.. J. Cardiol (2003) 92(Suppl. 4B):23K–29K.
  • SHEPHERD J, HUNNINGHAKE DB, STEIN EA et al.: Safety of rosuvastatin. Am. J. Cardiol (2004) 94:882–888.
  • OLSSON AG, MCTAGGART F, RAZAA: Rosuvastatin: a highly effective new-CoA reductase inhibitor. Cardiovasc. Drug Rev. (2002) 20:303–328.
  • ISTVAN ES, DEISENHOFER J: Structural mechanism for statin inhibition of HMG-CoA reductase. (2001) 292:1160–1164.
  • BUCKETT L, BALLARD P, R et al.: Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis (2000) 151:41. (Abstr. MoP29:W6).
  • NEZASA K, HIGAKI K, T et al.: Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. (2002) 30:1158–1163.
  • NEZASA K, TAKAO A, KIMURA K et al: Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. (2002) 32:715–727.
  • HUNNINGHAKE DB, STEIN EA, BAYS HE et al.: Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.. Artery Dis. (2004) 15:115–123.
  • CHAPMAN MJ, MCTAGGART F: Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. (2002) 2:33–37.
  • MARTIN D, WARWICK MJ, DANE AL et al.: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.. Ther. (2003) 25:2822–2835.
  • WARWICK MJ, DANE AL, RAZA A, SCHNECK DW: Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis (2000) 151:39. (Abstr. MoP19:W6).
  • MARTIN PD, MITCHELL PD, SCHNECK DW: Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning and evening administration in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 54:472–477.
  • FERDINAND K, DEEDWANIA PC, HAFFNER S et al: Design of 3 trials comparing rosuvastatin and atorvastatin in African American, South Asian, and Hispanic patients: ARIES, IRIS, and trials. Atheroscler. Suppl (2003) 4:83. (Abstr. IP–0290).
  • FERDINAND KC: Coronary heart diseaseand lipid-modifying treatment in African American patients. Am. Heart J. (2004) 14:774–782.
  • JACOBSON TA, CHIN MM, CURRY CL et al: Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch. Intern. Med. (1995) 155:1900–1906.
  • PRISANT LM, DOWNTON M, WATKINS LO et al: Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am. J. Cardiol (1996) 78:420–424.
  • FONG RL, WARD HJ: The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am. J. Med. (1997) 102:387–391.
  • FERDINAND KC, CLARK LT, NEAL RC et al.: Efficacy of statin therapy in African American patients with hypercholesterolemia: results from the ARIES trial. Circulation (2004) 110(Suppl. III):111-818111-819. (Abstr. 3780).
  • FERDINAND KC, WATSON KE, YCAS J et al.: Effect of statin therapy on C-reactive protein levels among African American patients with hypercholesterolemia: results from the ARIES trial. J. Am Coll Cardiol 2005) 45\(Suppl. 1):437A. (Abstr. 859–5).
  • MARTIN PD, DANE AL, NWOSE OM et al.: No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.. Pharmacol (2002) 42:1116–1121.
  • SIMONSON SG, MARTIN PD, MITCHELL Pet al.: Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur. J. Clin. Pharmacol (2003) 58:669–675.
  • MCCORMICK AD, MCKILLOP D, BUTTERS CJ et al.: ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. Clin. Pharmacol (2000) 40:1055. (Abstr. 46).
  • COOPER KJ, MARTIN PD, DANE AL et al.: The effect of erythromycin on the pharmacokinetics of rosuvastatin.. J. Clin. PharmacoL (2003) 59:51–56.
  • COOPER KJ, MARTIN PD, DANE AL et al.: Effect of itraconazole on the of rosuvastatin.. Pharmacol Ther. (2003) 73:322–329.
  • COOPER KJ, MARTIN PD, DANE AL et al.: Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br. J. Clin. Pharmacol. (2003) 55:94–99.
  • COOPER KJ, MARTIN PD, DANE AL et al.: The effect of fluconazole on the pharmacokinetics of rosuvastatin.. j Clin. Pharmacol. (2002) 58:527–531.
  • MARTIN PD, KEMP J, DANE AL et al.:No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharmacol (2002) 42:1352–1357.
  • MARTIN PD, DANE AL, DW et al.: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.. Ther. (2003) 25:459–471.
  • OLDEMEYER JB, LUND RJ, KOCH M et al.: Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology (2000) 94:127–128.
  • SOCHMAN J, PODZIMKOVA M: Not all statins are alike: induced rhabdomyolysis on changing from one statin to another one. Int. J. Cardiol. (2005) 99:145–146.
  • DAVIDSON MH: Rosuvastatin: a highlyefficacious statin for the treatment of dyslipidaemia. Expert Opin. Investig Drugs (2002) 11:125–141.
  • WIERZBICKI AS, MIKHAILIDIS DP: Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int. J. Cardiol (2002) 84:53–57.
  • BROWN W, BAYS HE, HASSMAN DR et al: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J. (2002) 144:1036–1043.
  • PAOLETTI R, FAHMY M, MAHLA G et al: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.. Risk (2001) 8:383–90.
  • BLASETTO JW, STEIN EA, WV et al: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol (2003) 91 (Suppl.):3C–10C.
  • SCHNECK DW, KNOPP RH, BALLANTYNE CM et al: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol (2003) 91:33–41.
  • SCHUSTER H, ON BEHALF OF THE MERCURY I STUDY GROUP: Effects of switching to rosuvastatin from atorvastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: MERCURY I trial. J. Am. Coll Cardiol (2003) 41(Suppl.):227A-228A. [Abstr. 1010–149].
  • STEIN E, STRUTT K, WORTH H et al: Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.. J. Cardiol (2003) 92:1287–1293.
  • CASLAKE MJ, STEWART G, DAY SP et al.: Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis (2003) 171:245–253.
  • LAW MR, WALD NJ, RUDNICKA AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 326:1423–1427.
  • DEEDWANIA PC: Metabolic syndromeand vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation (2004) 109:2–4.
  • ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24:683–689.
  • LAKKA HM, LAAKSONEN DE, LAKKA TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA (2002) 288:2709–2716.
  • SATTAR N, GAW A, SCHERBAKOVA 0 et al.: Metabolic syndrome with and without C-reactive protein as a predicator of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 108:414–419.
  • NINOMIYA JK, LITALIEN G, CRIQUI MH et al: Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation (2004) 109:42–46.
  • FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA (2002) 287:356–359.
  • DEEDWANIA PC, DB, BAYS HE et al: Effects of rosuvastatin, atorvastatin, simvastatin and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am. J. Cardiol (2005) 95:360–366.
  • STALENHOEF AFH, CM, TUOMILEHTO J et al.: A Comparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Diabeto/ogia (2004) 47(Suppl.):A409–1147.
  • WOLFFENBUTTEL BHR, AAM, VINCENT HH et al.: Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes-CORALL study.. Med. (2005) 257:531–539.
  • [NO AUTHORS LISTED]: Randomisedtrial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • SACKS FM, PFEFFER Mk MOYE LA et al: The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl. J. Med. (1996) 335:1001–1009.
  • SHEPHERD J, COBBE SM, FORD I et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333:1301–1307.
  • DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and woman with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615–1622.
  • NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. /AMA (2004) 291:1071–1080.
  • NISSEN S: Design and methodology of A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden: the ASTEROID study. Atheroscler. Suppl. (2003) 4(1):27. (Abstr. IP–0037).
  • GROUSE JR III, GROBBEE DE, O'LEARY DR et al.: Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis-the rationale and methodology of the METEOR study. Cardiovasc. Drugs Ther. (2004) 18:231–238.
  • CHU B,HATSUKAMI TS, POLISSAR NL et al.: Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using non-invasive magnetic resonance imaging. Stroke (2004) 35:2444–2448.
  • FELLSTROM B, ZANNAD F, R et al.: A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events-the AURORA study. Niphrol. Dial. Transplant. (2003) 18\(Suppl. 4):713. (Abstr. W520).
  • SCHUSTER H, FOX JC: Investigating cardiovascular risk reduction: the rosuvastatin GALAXY programme. Expert Opin. Pharmacother. (2004) 5:1187–1200.
  • RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N Engl. J. Med. (2005) 352:20–28.
  • NISSEN SE, TUZCU EM, P et al: Statin therapy, LDL cholesterol, C-reactive protein, and artery disease. N Engl. J. Med. (2005) 352:29–38.
  • RIDKER PM on behalf of the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation (2003) 108:2292–2297.
  • VIDT DG, CRESSMAN MD, HARRIS S et al.: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102:52–60.
  • SIDAWAY JE, DAVIDSON RG, MCTAGGART F et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Niphrol. (2004); 15:2258–2265.
  • VERHULST A. D'HAESE PC, DE BROE ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am. Soc. Niphrol. (2004) 15:2249–2257.

Websites

  • http://www.americanheart.org/ presenterjhtml?identifier=3000090 Accessed 20 July, 2005.
  • http://www.pharma.us.novartis.com/ product/pi/pdf/Lescol.pdf Full presecribing information for Lescol®. Accessed 11 July, 2005.
  • http://www.pfizer.com/pfizer/download/ uspi_lipitor.pdf presecribing information for Lipitor®. Accessed 11 July, 2005.
  • http://www.merck.com/product/usa/ pi_circulars/m/mevacor/mevacor_pi.pdf Full presecribing information for Mevacor®. Accessed 11 July, 2005.
  • http://www.merck.com/product/usa/ pi_circulars/z/zocor/zocor_pi.pdf Full presecribing information for Zocor®. Accessed 11 July, 2005.
  • http://www.bms.com/cgi-bin/.pl?sql=select%2OPPI%20from°/020 TB_PRODUCT_PPI%20where°/02OPPI_S EQ=568ckey=PPI presecribing information for Pravachol®. Accessed 11 July, 2005.
  • http://www.astrazeneca-us.com/pi/ crestor.pdf presecribing information for Crestor®. Accessed 11 July, 2005.
  • http://www.fcla.gov/cder/drug/infopage/ rosuvastatin/default.htm FDA alert. Accessed 20 July, 2005.
  • http://www.rosuvastatininformation.com Accessed November 30th 2004. Rosuvastatin information website: rosuvastatin clinical information - postmarketing experience, safety information 30 November, 2004.
  • http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search. Label_ApprovalHistory#apphist 22 July, 2005.
  • http://www.fcla.gov/cder/drug/infopage/ rosuvastatin/crestor_CP.pdf 22 July, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.